Literature DB >> 23246510

Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum® assay.

Andreas Sauerbrei1, Susanne Vödisch, Kathrin Bohn, Michael Schacke, Simon Gronowitz.   

Abstract

Rapid alternative methods are required to evaluate easily acyclovir (ACV) sensitivity of clinical herpes simplex virus (HSV) isolates. The objective of this study was to screen 54 ACV-sensitive and 41 ACV-resistant clinical HSV-1 isolates, well characterized by phenotypic and genotypic methods, for the phosphorylation activity of the viral thymidine kinase (TK) using a commercially available and modified non-radioactive DiviTum® test on the basis of an indirect enzyme linked immunosorbent assay. The ACV-sensitive HSV-1 isolates had high TK activity values between 31.5±6.4 DiviTum® Units per liter (DU/L) and 487.4±60.1 DU/L. The mean activity of all ACV-sensitive isolates was calculated as 212.3±15.7 DU/L. By contrast, the mean activity of all ACV-resistant HSV-1 isolates was significantly lower at 5.5±1.3 DU/L. Out of the 41 ACV-resistant HSV-1 isolates, 38 had no or very low phosphorylation activities of the viral TK between 0 DU/L and 9.3±3.2 DU/L. The remaining three ACV-resistant viral isolates had TK activities between 44.6±5.1 DU/L and 80.9±13.3D U/L. In conclusion, the modified DiviTum® test can be used to screen HSV-1 isolates for their sensitivity to ACV. Acyclovir-sensitive HSV-1 isolates show TK activities >30 DU/L and ACV-resistant isolates have activity values <10 DU/L. However, single ACV-resistant HSV-1 isolates can have TK activity values >30 DU/L. These strains are most likely ACV-resistant TK-altered mutants, but no evidence was provided for an alteration of the TK.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23246510     DOI: 10.1016/j.jviromet.2012.12.001

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  5 in total

1.  Acyclovir resistance in herpes simplex virus type I encephalitis: a case report.

Authors:  Andreas Sauerbrei
Journal:  J Neurovirol       Date:  2017-06-21       Impact factor: 2.643

2.  Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance.

Authors:  Susanne Schmidt; Kathrin Bohn-Wippert; Peter Schlattmann; Roland Zell; Andreas Sauerbrei
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

3.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Prevalence of Intrathecal Acyclovir Resistant Virus in Herpes Simplex Encephalitis Patients.

Authors:  Johanna G Mitterreiter; Maarten J Titulaer; Gijsbert P van Nierop; Jeroen J A van Kampen; Georgina I Aron; Albert D M E Osterhaus; Georges M G M Verjans; Werner J D Ouwendijk
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

5.  Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility.

Authors:  Anne-Kathrin Brunnemann; Kristin Liermann; Stefanie Deinhardt-Emmer; Gregor Maschkowitz; Anja Pohlmann; Beate Sodeik; Helmut Fickenscher; Andreas Sauerbrei; Andi Krumbholz
Journal:  Sci Rep       Date:  2016-07-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.